An interventional study of L-carnitine and Standard care in Respiratory Distress Syndrome, sponsored by Muhammad Aamir Latif. Recruiting at 1 site in Pakistan. Open to participants aged 1 Hour to 24 Hours. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Muhammad Aamir Latif · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Respiratory Distress Syndrome with a site in Pakistan — 2 open to participants now, 2 under way, none of them phase 3. Respiratory Distress Syndrome · Pakistan.
Among the 12 studies in Respiratory Distress Syndrome with a site in Pakistan, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, and was the 9th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →2 of the 12 studies in Respiratory Distress Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:
Aga Khan University · Sites in Pakistan
Ages 0 hrs–6 hrs
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 1 Hour to 24 Hours · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 86 across the 10 interventional studies, 1,027 across the 2 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 9 most frequent:
Muhammad Aamir Latif is the lead sponsor of 59 studies on the registry; 9 are open to participants now.
Muhammad Aamir Latif has 2 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Respiratory Distress Syndrome with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07837141Aga Khan UniversityNoninvasive High Frequency Oscillatory Ventilation Versus Nasal Intermittent Mandatory Ventilation for Respiratory Distress Syndrome in Preterm Neonates | 2027-11-10 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Respiratory Distress Syndrome with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current study is planned to see the effect of L-carnitine supplementation in preterm neonates suffering from RDS among the local population, as there is no such evidence available for the local population and there are conflicting statistics regarding the discharge rate of these neonates.
Given the contradictory results (discharge rate), additional rigorously designed studies are necessary to elucidate the impact of L-carnitine supplementation on short-term neonatal outcomes, including weight gain, discharge rate, and mortality. The proposed research aims to fill this knowledge gap by systematically evaluating the clinical efficacy and safety of L-carnitine supplementation in L-carnitine-deficient neonates. The findings would provide evidence-based suggestions on whether L-carnitine is a useful, safe, and potentially beneficial adjunct in managing preterm neonates with RDS, particularly in addressing metabolic needs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive L-carnitine at a therapeutic dosage of 30 mg/kg/day, in conjunction with a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.
Drug: L-carnitine · Drug: Standard care
Patients will get only a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.
Drug: Standard care
Patients will receive L-carnitine at a therapeutic dosage of 30 mg/kg/day, in conjunction with a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.
Patients will get a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.
Mortality
If a patient will die in the hospital, it will be considered as mortality, otherwise taken as discharged alive.
Time frame: 30 days
Change in Weight
Change in weight will be measured at discharge and compared with the baseline measure. An increase in the weight from baseline will be considered effectiveness of the treatment.
Time frame: 30 days
Plan to share: No — Data can be shared on a reasonable request.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jun 2026, 5 months after the start.
Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 5 months is below that.
Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carnitine
Respiratory Distress Syndrome →
Muhammad Aamir Latif